# Kanso Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kanso-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Total disclosed funding: $0.1M
- Latest round: Seed (Jun 1, 2026)
- Investors on record: 5

## About

Founded in 2021 and based in Israel, Kanso Diagnostics operates as a developer of a molecular diagnostics platform capable of at-home diagnostics with PCR and antigen tests. The company was co-founded by Omer Stoller (CEO) and Roy Rabinowitz. In November 2023, the firm raised an amount of Seed funding from investors Peregrine Ventures, Israel Innovation Authority, Becton, Dickinson and Company, Shaare Zedek Medical Center, and Bristol-Myers Squibb Company.

Kanso Diagnostics' product is its proprietary molecular diagnostics platform. This platform leverages CRISPR technology within a compact lab-on-a-chip device, enabling users to perform accurate bacterial and viral infection diagnostics conveniently at home. The system can be accessed by individuals without specialized medical training.

The company plans to use the November 2023 funding to support product development.

## Funding rounds

- Seed, Jun 1, 2026, $0.1M — Peregrine Ventures
- Seed, Jul 1, 2025 — Peregrine Ventures
- Seed, Nov 1, 2023 — Peregrine Ventures, Bristol-Myers Squibb Company, Becton, Dickinson and Company, Israel Innovation Authority, Shaare Zedek Medical Center

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Seed
- Bristol-Myers Squibb Company — Seed
- Becton, Dickinson and Company — Seed
- Israel Innovation Authority — Seed
- Shaare Zedek Medical Center — Seed